Free Trial

Keros Therapeutics (NASDAQ:KROS) Downgraded by BTIG Research to "Neutral"

Keros Therapeutics logo with Medical background

BTIG Research downgraded shares of Keros Therapeutics (NASDAQ:KROS - Free Report) from a buy rating to a neutral rating in a research note issued to investors on Thursday, MarketBeat reports.

A number of other research analysts have also weighed in on KROS. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Guggenheim reaffirmed a "buy" rating and issued a $102.00 price objective (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. Wedbush reiterated an "outperform" rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Wells Fargo & Company boosted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $95.22.

Read Our Latest Stock Report on Keros Therapeutics

Keros Therapeutics Stock Down 73.2 %

NASDAQ KROS traded down $50.22 during trading hours on Thursday, reaching $18.43. The company's stock had a trading volume of 14,631,993 shares, compared to its average volume of 437,409. Keros Therapeutics has a 1 year low of $15.67 and a 1 year high of $73.00. The company has a market capitalization of $746.54 million, a price-to-earnings ratio of -3.08 and a beta of 1.20. The firm's 50-day moving average price is $60.78 and its 200-day moving average price is $53.07.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business's quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.33) earnings per share. Equities research analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of large investors have recently bought and sold shares of KROS. Geode Capital Management LLC lifted its holdings in Keros Therapeutics by 6.8% during the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock valued at $42,146,000 after buying an additional 46,041 shares in the last quarter. Barclays PLC increased its position in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after acquiring an additional 35,022 shares during the period. Wellington Management Group LLP bought a new stake in shares of Keros Therapeutics during the third quarter valued at approximately $868,000. Point72 DIFC Ltd raised its stake in shares of Keros Therapeutics by 9.8% during the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company's stock valued at $1,118,000 after acquiring an additional 1,715 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after purchasing an additional 577,220 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Read More

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

→ Did You See Trump’s Bombshell Exec. Order 001? (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in Keros Therapeutics right now?

Before you consider Keros Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.

While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines